Methemoglobinemia medical therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 10: Line 10:
==Medical Therapy==       
==Medical Therapy==       


*Initial management of [[methemoglobinemia)) patients includes administration of supplemental [[oxygen]] and if the toxin is still present on the skin, the clothes should be promptly removed and the skin washed. If the patient cannot provide information on the cause of the presenting symptoms, we could check the blood levels of [[MetHb]] and also perform [[gastric lavage]]. In asymptomatic patients, we can measure the serum levels of MetHb multiple times until the levels normalize, which usually happens.<ref>{{Rev Bras Anestesiol. 2008 Nov-Dec;58(6):651-64. Methemoglobinemia: from diagnosis to treatment. [Article in English, Portuguese] do Nascimento TS1, Pereira RO, de Mello HL, Costa J. pmid=19082413}}</ref> <ref>{{South Med J. 2011 Nov;104(11):757-61. doi: 10.1097/SMJ.0b013e318232139f. Methemoglobinemia: pathogenesis, diagnosis, and management. Skold A1, Cosco DL, Klein R. pmid=22024786 }}</ref>  
*Initial management of [[methemoglobinemia]] patients includes administration of supplemental [[oxygen]] and if the toxin is still present on the skin, the clothes should be promptly removed and the skin washed. If the patient cannot provide information on the cause of the presenting symptoms, we could check the blood levels of [[MetHb]] and also perform [[gastric lavage]]. In asymptomatic patients, we can measure the serum levels of MetHb multiple times until the levels normalize, which usually happens.<ref name="pmid19082413">{{cite journal| author=do Nascimento TS, Pereira RO, de Mello HL, Costa J| title=Methemoglobinemia: from diagnosis to treatment. | journal=Rev Bras Anestesiol | year= 2008 | volume= 58 | issue= 6 | pages= 651-64 | pmid=19082413 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19082413  }} </ref> <ref name="pmid22024786">{{cite journal| author=Skold A, Cosco DL, Klein R| title=Methemoglobinemia: pathogenesis, diagnosis, and management. | journal=South Med J | year= 2011 | volume= 104 | issue= 11 | pages= 757-61 | pmid=22024786 | doi=10.1097/SMJ.0b013e318232139f | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22024786 }} </ref>


*Patients who are symptomatic and have [[MetHb]] levels above 20% or less than 20% but with multiple comorbidities, should be admitted to the hospital and treated with intravenous (IV) [[methylene blue]] as this is the first-line [[antidotal]] agent, 1% solution (10mg/ml) 1-2mg/kg administered intravenously slowly over five minutes followed by IV flush with [[normal saline]]. [[Methylene blue]] restores the iron in [[hemoglobin]] to its normal ([[reduced]]) oxygen-carrying state. This is achieved through the [[enzyme induction|enzyme inducing]] effect of [[methylene blue]] on levels of [[diaphorase II]] ([[NADPH methemoglobin reductase]]). [[Diaphorase II]] normally contributes only a small percentage of the [[red blood cells)) reducing capacity but is pharmacologically activated by exogenous cofactors, such as [[methylene blue]], to 5 times its normal level of activity.<ref>{{Del Med J. 2011 Jul;83(7):203-8. Methemoglobinemia: a systematic review of the pathophysiology, detection, and treatment. Ashurst J1, Wasson M. pmid=PMID: 21954509}}</ref>  
*Patients who are symptomatic and have [[MetHb]] levels above 20% or less than 20% but with multiple comorbidities, should be admitted to the hospital and treated with intravenous (IV) [[methylene blue]] as this is the first-line [[antidotal]] agent, 1% solution (10mg/ml) 1-2mg/kg administered intravenously slowly over five minutes followed by IV flush with [[normal saline]]. [[Methylene blue]] restores the iron in [[hemoglobin]] to its normal ([[reduced]]) oxygen-carrying state. This is achieved through the [[enzyme induction|enzyme inducing]] effect of [[methylene blue]] on levels of [[diaphorase II]] ([[NADPH methemoglobin reductase]]). [[Diaphorase II]] normally contributes only a small percentage of the [[red blood cells)) reducing capacity but is pharmacologically activated by exogenous cofactors, such as [[methylene blue]], to 5 times its normal level of activity.<ref name="pmid21954509">{{cite journal| author=Ashurst J, Wasson M| title=Methemoglobinemia: a systematic review of the pathophysiology, detection, and treatment. | journal=Del Med J | year= 2011 | volume= 83 | issue= 7 | pages= 203-8 | pmid=21954509 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21954509 }} </ref>


*[[Methylene blue]] should not be used in patients with [[G6PD deficiency]], as the [[antidote]] requires [[G6PD]] to work. The use of [[methylene blue]] in [[G6PD deficient]] patients can lead to [[hemolysis]]. In [[G6PD deficient]] patients we can use [[exchange transfusion]] as treatment. [[Exchange transfusion]] as the name implies, replaces abnormal [[hemoglobin]] with normal [[hemoglobin]]). We can also use it to treat patients presenting with severe symptoms and unresponsive to [[methylene blue]] treatment.<ref>{{BMJ Case Rep. 2018 Mar 28;2018. pii: bcr-2017-223369. doi: 10.1136/bcr-2017-223369.
*[[Methylene blue]] should not be used in patients with [[G6PD deficiency]], as the [[antidote]] requires [[G6PD]] to work. The use of [[methylene blue]] in [[G6PD deficient]] patients can lead to [[hemolysis]]. In [[G6PD deficient]] patients we can use [[exchange transfusion]] as treatment. [[Exchange transfusion]] as the name implies, replaces abnormal [[hemoglobin]] with normal [[hemoglobin]]). We can also use it to treat patients presenting with severe symptoms and unresponsive to [[methylene blue]] treatment.<ref name="pmid29592989">{{cite journal| author=Rehman A, Shehadeh M, Khirfan D, Jones A| title=Severe acute haemolytic anaemia associated with severe methaemoglobinaemia in a G6PD-deficient man. | journal=BMJ Case Rep | year= 2018 | volume= 2018 | issue=  | pages=  | pmid=29592989 | doi=10.1136/bcr-2017-223369 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29592989 }} </ref>
Severe acute haemolytic anaemia associated with severe methaemoglobinaemia in a G6PD-deficient man.
Rehman A1,2, Shehadeh M2, Khirfan D2, Jones A2. pmid=29592989}}</ref>


*The use of [[methylene blue]] is contraindicated in patients concurrently taking [[serotonergic psychiatric drugs]], as the risk for inducing [[serotonin syndrome]] increases. Furthermore, [[methylene blue]] is not used in patients with [[Hemoglobin M]] (Hb M), [[nicotinamide adenine dinucleotide phosphate ([[NADPH]]) methemoglobin reductase]] (ie, [[diaphorase II]] deficiency]] and [[sulfhemoglobinemia]], due to lack of effect. In such cases we can use [[hyperbaric oxygen]] treatment, that allows tissue oxygenation via dissolving [[oxygen]] directly in the [[plasma]]. <ref>{{Toxicol Rev. 2003;22(1):13-27. Occupational methaemoglobinaemia. Mechanisms of production, features, diagnosis and management including the use of methylene blue.
*The use of [[methylene blue]] is contraindicated in patients concurrently taking [[serotonergic psychiatric drugs]], as the risk for inducing [[serotonin syndrome]] increases. Furthermore, [[methylene blue]] is not used in patients with [[Hemoglobin M]] (Hb M), [[nicotinamide adenine dinucleotide phosphate ([[NADPH]]) methemoglobin reductase]] (ie, [[diaphorase II]] deficiency]] and [[sulfhemoglobinemia]], due to lack of effect. In such cases we can use [[hyperbaric oxygen]] treatment, that allows tissue oxygenation via dissolving [[oxygen]] directly in the [[plasma]]. <ref name="pmid14579544">{{cite journal| author=Bradberry SM| title=Occupational methaemoglobinaemia. Mechanisms of production, features, diagnosis and management including the use of methylene blue. | journal=Toxicol Rev | year= 2003 | volume= 22 | issue= 1 | pages= 13-27 | pmid=14579544 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14579544 }} </ref>
Bradberry SM1. pmid=14579544}}</ref>  


*Genetically induced chronic low-level [[methemoglobinemia]] may be treated with oral [[methylene blue]] daily, [[ascorbic acid]] or [[riboflavin]] in order to decrease [[cyanosis]].
*Genetically induced chronic low-level [[methemoglobinemia]] may be treated with oral [[methylene blue]] daily, [[ascorbic acid]] or [[riboflavin]] in order to decrease [[cyanosis]].


==References==
==References==

Revision as of 13:17, 15 June 2018

Methemoglobinemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Methemoglobinemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Methemoglobinemia medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Methemoglobinemia medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Methemoglobinemia medical therapy

on Methemoglobinemia medical therapy

Methemoglobinemia medical therapy in the news

Blogs on Methemoglobinemia medical therapy

Directions to Hospitals Treating Methemoglobinemia

Risk calculators and risk factors for Methemoglobinemia medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Template:Aksiniya K. Stevasarova, M.D.

Overview

Methemoglobinemia should be promptly treated once diagnosed.

Medical Therapy

  • Initial management of methemoglobinemia patients includes administration of supplemental oxygen and if the toxin is still present on the skin, the clothes should be promptly removed and the skin washed. If the patient cannot provide information on the cause of the presenting symptoms, we could check the blood levels of MetHb and also perform gastric lavage. In asymptomatic patients, we can measure the serum levels of MetHb multiple times until the levels normalize, which usually happens.[1] [2]

References

  1. do Nascimento TS, Pereira RO, de Mello HL, Costa J (2008). "Methemoglobinemia: from diagnosis to treatment". Rev Bras Anestesiol. 58 (6): 651–64. PMID 19082413.
  2. Skold A, Cosco DL, Klein R (2011). "Methemoglobinemia: pathogenesis, diagnosis, and management". South Med J. 104 (11): 757–61. doi:10.1097/SMJ.0b013e318232139f. PMID 22024786.
  3. Ashurst J, Wasson M (2011). "Methemoglobinemia: a systematic review of the pathophysiology, detection, and treatment". Del Med J. 83 (7): 203–8. PMID 21954509.
  4. Rehman A, Shehadeh M, Khirfan D, Jones A (2018). "Severe acute haemolytic anaemia associated with severe methaemoglobinaemia in a G6PD-deficient man". BMJ Case Rep. 2018. doi:10.1136/bcr-2017-223369. PMID 29592989.
  5. Bradberry SM (2003). "Occupational methaemoglobinaemia. Mechanisms of production, features, diagnosis and management including the use of methylene blue". Toxicol Rev. 22 (1): 13–27. PMID 14579544.

Template:WH Template:WS